Cytoreductive Surgery in Ovarian Cancer
Cytoreductive surgery aims to remove all visible disease in advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Complete macroscopic resection is associated with the greatest survival benefit. Feasibility of enhanced recovery pathways for cytoreduction, with or without hyperthermic intraperitoneal chemotherapy (HIPEC), has been demonstrated in multicenter studies【S1】.
Indications and Timing
- Patients with stage III‑IV disease are evaluated for primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS)【S3】.
- Candidates for PCS should have disease amenable to complete macroscopic resection based on imaging and clinical assessment【S2】.
- NACT is recommended when extensive disease or poor performance status makes optimal PCS unlikely【S3】.
Surgical Goals and Extent
- Goal: no residual nodules >1 cm; ideally no gross disease.
- Standard procedures include total abdominal hysterectomy, bilateral salpingo‑oophorectomy, omentectomy, peritoneal stripping, and resection of involved diaphragmatic, bowel, and mesenteric surfaces as needed【S4】.
- Complete cytoreduction remains the strongest prognostic factor, but benefit varies with tumor distribution; involvement of ileocecal region or small bowel predicts inferior survival even after complete resection【S7】.
Patient Selection and Pre‑operative Assessment
- Multidisciplinary evaluation by a gynecologic oncologist is required.
- Baseline work‑up includes CA‑125, contrast‑enhanced CT of abdomen/pelvis, and chest imaging【S3】.
- Structured radiologic reporting using the ESUR lexicon improves pre‑operative staging accuracy【S2】.
- Assessment of performance status, comorbidities, and anticipated surgical morbidity guides selection for PCS versus NACT‑IDS【S3】.
Role of HIPEC
- HIPEC can be administered at the time of cytoreduction for selected patients with advanced or recurrent disease.
- Systematic reviews of randomized trials suggest a potential progression‑free survival advantage, but overall survival benefit remains uncertain【S10】.
- National guidelines vary on HIPEC recommendations; consensus statements highlight the need for institutional expertise and patient selection criteria【S9】.
Peri‑operative Optimization (ERAS)
- Enhanced Recovery After Surgery (ERAS) protocols are feasible in cytoreductive procedures and may reduce length of stay and postoperative complications【S1】.
- Core ERAS components include pre‑operative counseling, multimodal analgesia, goal‑directed fluid therapy, early mobilization, and early oral intake.
Prognostic Considerations Post‑Cytoreduction
- Complete macroscopic resection correlates with improved long‑term survival.
- Residual disease >1 cm, small‑bowel involvement, and high tumor burden are independent predictors of poorer outcomes despite optimal surgery【S7】.
Follow‑up and Surveillance
- Post‑operative imaging and serial CA‑125 measurements are recommended for surveillance, adhering to ESUR follow‑up guidelines【S2】.
- Ongoing assessment for eligibility for maintenance therapies, such as PARP inhibitors, should be integrated into survivorship care【S8】.